Frazier Life Sciences Public Fund, L.P. 13D and 13G filings for Maze Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-13 5:31 pm Purchase | 2025-12-31 | 13G | Maze Therapeutics, Inc. MAZE | Frazier Life Sciences Public Fund, L.P. | 4,342,266 9.000% | 989,351 (+29.51%) | Filing |
| 2025-08-14 1:43 pm Sale | 2025-06-30 | 13G | Maze Therapeutics, Inc. MAZE | Frazier Life Sciences Public Fund, L.P. | 3,352,915 7.700% | -1,098,424 (-24.68%) | Filing |
| 2025-04-29 09:59 am Purchase | 2025-04-25 | 13G | Maze Therapeutics, Inc. MAZE | Frazier Life Sciences Public Fund, L.P. | 4,451,339 10.200% | 322,339 (+7.81%) | Filing |
| 2025-04-29 09:58 am Purchase | 2025-03-31 | 13G | Maze Therapeutics, Inc. MAZE | Frazier Life Sciences Public Fund, L.P. | 4,129,000 9.400% | 935,100 (+29.28%) | Filing |
| 2025-02-10 10:55 am Purchase | 2025-02-03 | 13G | Maze Therapeutics, Inc. MAZE | Frazier Life Sciences Public Fund, L.P. | 3,193,900 7.300% | 3,193,900 (New Position) | Filing |